Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 18/20 | 0.70 |
| ▸ | HTR2C | P28335 | 17/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16627293 | 0.86 | HTR2A (0.51) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL6034142 | 0.81 | HTR2A (0.76) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL14625270 | 0.81 | HTR2A (0.76) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL2338740 | 0.81 | HTR2A (1.00) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL16627263 | 0.80 | HTR2C (0.48) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL12754369 | 0.78 | HSD11B1 (0.66) | HTR2AHTR2CL3MBTL1 | |
| SCHEMBL6034623 | 0.78 | HTR2A (0.72) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL7167510 | 0.77 | L3MBTL1 (0.51) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL12315354 | 0.76 | HTR2A (0.74) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL2402025 | 0.74 | L3MBTL1 (0.44) | HTR2AHTR2CL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822656-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RES INST ROYAL (GB) | 2016-10-19 | — | — | EP | disclosed |
| US-9193689-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-11-24 | — | — | US | disclosed |
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP11 | HTR2A 693/4885HTR2C 974/4885L3MBTL1 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.